Narcolepsy: an interface among neurology, immunology, sleep, and genetics.

Narcolepsia: uma interface entre neurologia, imunologia, sono e genética.

Publisher: Thieme Country of Publication: Germany NLM ID: 0125444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1678-4227 (Electronic) Linking ISSN: 0004282X NLM ISO Abbreviation: Arq Neuropsiquiatr Subsets: MEDLINE

Publication: 2022- : [Stuttgart] : Thieme
Original Publication: São Paulo.

Narcolepsy*/drug therapy ; Narcolepsy*/genetics ; Narcolepsy*/diagnosis ; Cataplexy*/drug therapy ; Cataplexy*/genetics ; Cataplexy*/diagnosis ; Neurology*; Humans ; Quality of Life ; Sleep

Narcolepsy is a primary disorder of the central nervous system resulting from genetic, environmental, and immunological interactions defined as excessive daytime sleepiness plus cataplexy, hallucinations, sleep paralysis, and sleep fragmentation. The pathophysiology is not entirely known, but the interaction among genetic predisposition, environmental exposition, and immune component with consequent hypocretin-1 deficiency is the model to explain narcolepsy type I. The mechanism of narcolepsy type II is less understood. There is a delay of over ten years for the diagnosis of narcolepsy around the world. Patients with narcolepsy have many comorbidities with a negative impact on quality of life. The treatment of narcolepsy must contain an educational approach for the family, coworkers, and patients. Scheduled naps and sleep hygiene are essential to minimize the dose of medications. Much progress has been seen in the pharmacological treatment of narcolepsy with new stimulants, different presentations of oxybate, and recent studies with orexin agonists. Narcolepsy is a rare disease that needs to be more understood and highlighted to avoid delayed diagnosis and severe disabilities in patients.
Competing Interests: There is no conflict of interest to declare.
(The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/).)

Sleep Med. 2020 Jun;70:55-59. (PMID: 32197225)
Pediatr Neurol. 2009 Jul;41(1):9-16. (PMID: 19520267)
J Sleep Res. 2021 Dec;30(6):e13387. (PMID: 34173288)
Sleep Med. 2021 Feb;78:57-62. (PMID: 33385780)
Arq Neuropsiquiatr. 2010 Oct;68(5):712-5. (PMID: 21049180)
Sleep Med. 2023 Nov;111:101-104. (PMID: 37748251)
J Sleep Res. 2018 Apr;27(2):268-272. (PMID: 28568319)
Sleep Med. 2014 May;15(5):502-7. (PMID: 24780133)
Eur J Neurol. 2021 Sep;28(9):2815-2830. (PMID: 34173695)
Sleep Sci. 2022 Jan-Mar;15(Spec 1):278-284. (PMID: 35273778)
Sleep Sci. 2018 Jul-Aug;11(4):215-216. (PMID: 30746038)
J Sleep Res. 2019 Jun;28(3):e12715. (PMID: 29923259)
Braz J Psychiatry. 2020;42(3):314-316. (PMID: 31859793)
Neurol Ther. 2023 Dec;12(6):1805-1820. (PMID: 37755650)
Cell. 1998 Mar 6;92(5):1 page following 696. (PMID: 9527442)
Arq Neuropsiquiatr. 2007 Jun;65(2B):423-7. (PMID: 17665008)
J Clin Invest. 2010 Mar;120(3):713-9. (PMID: 20160349)
J Sleep Res. 2000 Mar;9(1):89-96. (PMID: 10733694)
Sleep Breath. 2020 Dec;24(4):1675-1684. (PMID: 32215834)
Sleep. 2023 Jul 11;46(7):. (PMID: 36971181)
Exp Neurol. 2003 Dec;184(2):1010-6. (PMID: 14769395)
CNS Drugs. 2020 Jul;34(7):773-784. (PMID: 32588401)
Sleep. 2006 Nov;29(11):1429-38. (PMID: 17162989)
Arq Neuropsiquiatr. 2021 Sep;79(9):808-815. (PMID: 34495122)
Sleep Sci. 2019 Jan-Feb;12(1):49-52. (PMID: 31105895)
Neuroscience. 2002;112(2):355-65. (PMID: 12044453)
Continuum (Minneap Minn). 2023 Aug 1;29(4):1045-1070. (PMID: 37590822)
Arq Neuropsiquiatr. 2017 Sep;75(9):682-683. (PMID: 28977155)
Sleep Sci. 2022 Oct-Dec;15(4):515-573. (PMID: 36419815)
BMC Neurol. 2022 Nov 18;22(1):439. (PMID: 36401198)
Arq Neuropsiquiatr. 1997 Sep;55(3A):423-6. (PMID: 9629359)
PLoS One. 2013;8(1):e53707. (PMID: 23349733)
Sleep Med. 2018 May;45:146-147. (PMID: 29523463)
Nat Sci Sleep. 2017 Apr 26;9:127-133. (PMID: 28490912)
Hum Immunol. 2011 Oct;72(10):817-20. (PMID: 21669245)
Clin Drug Investig. 2009;29(9):613-23. (PMID: 19663523)
Neurology. 1998 Feb;50(2 Suppl 1):S16-22. (PMID: 9484418)
Sleep Med. 2020 Dec;76:134-139. (PMID: 33166827)
Lancet. 2000 Jan 1;355(9197):39-40. (PMID: 10615891)
Nat Rev Neurol. 2019 Sep;15(9):519-539. (PMID: 31324898)
Sleep Med. 2017 Oct;38:162-163. (PMID: 28889987)
Ann Neurol. 2002 May;51(5):578-84. (PMID: 12112103)
Sleep Med Rev. 2018 Apr;38:177-186. (PMID: 28847694)
Sleep Med. 2017 Jun;34:7-12. (PMID: 28522101)
Arq Neuropsiquiatr. 2007 Jun;65(2A):336-7. (PMID: 17607439)
J Psychiatr Res. 2024 Jan;169:42-48. (PMID: 38000183)
Sleep. 2007 Jan;30(1):13-26. (PMID: 17310860)
Nat Sci Sleep. 2023 Jul 28;15:579-591. (PMID: 37533626)
N Engl J Med. 2015 Dec 31;373(27):2654-62. (PMID: 26716917)
Sleep Med. 2019 Sep;61:118-121. (PMID: 31427075)
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12323-E12332. (PMID: 30541895)
Sleep Med. 2020 Aug;72:75-81. (PMID: 32554327)
Sleep Med. 2020 Oct;74:297. (PMID: 32882661)
Sleep. 2013 Feb 01;36(2):175-81. (PMID: 23372264)
Sleep. 1991 Dec;14(6):540-5. (PMID: 1798888)
Sleep Med. 2002 Jul;3(4):335-9. (PMID: 14592196)
Sleep Med. 2011 Jan;12(1):12-8. (PMID: 21145280)
Behav Neurol. 2018 Oct 15;2018:1671072. (PMID: 30410634)
Arch Ital Biol. 2004 Jul;142(4):479-86. (PMID: 15493549)
Sleep Med. 2018 Dec;52:234. (PMID: 30274905)
N Engl J Med. 2023 Jul 27;389(4):309-321. (PMID: 37494485)
Ann Neurol. 2004 Dec;56(6):905-8. (PMID: 15562415)
Arq Neuropsiquiatr. 2020 Jun 29;78(8):488-493. (PMID: 32627808)
Lancet Neurol. 2014 Jun;13(6):600-13. (PMID: 24849861)
Sleep. 2019 Jul 8;42(7):. (PMID: 31004158)

Local Abstract: [Publisher, Portuguese] A narcolepsia é um distúrbio primário do sistema nervoso central resultante das interações genéticas, ambientais e imunológicas definidas como sonolência diurna excessiva mais cataplexia, alucinações, paralisia do sono e fragmentação do sono. A fisiopatologia não é completamente conhecida, mas a interação entre predisposição genética, exposição ambiental e componente imunológico com consequente deficiência de hipocretina-1 é o modelo para explicar a narcolepsia tipo I. O mecanismo da narcolepsia tipo II é menos compreendido. Há um atraso de mais de dez anos para o diagnóstico da narcolepsia em todo o mundo. Pacientes com narcolepsia apresentam muitas comorbidades com impacto negativo na qualidade de vida. O tratamento da narcolepsia deve conter uma abordagem educativa para a família, colegas de trabalho e pacientes. Cochilos programados e higiene do sono são importantes para minimizar a dose dos medicamentos. Muito progresso foi observado no tratamento farmacológico da narcolepsia com novos estimulantes, diferentes apresentações de oxibato e estudos recentes com agonistas de orexina. A narcolepsia é uma doença rara que precisa ser mais compreendida e destacada para evitar atrasos no diagnóstico e incapacidades graves nos pacientes.

Date Created: 20240402 Date Completed: 20240404 Latest Revision: 20240406

20240406

PMC10987254

10.1055/s-0044-1779299

38565187